Insider Selling: Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells 835 Shares of Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 835 shares of the business’s stock in a transaction on Thursday, January 23rd. The stock was sold at an average price of $42.00, for a total value of $35,070.00. Following the sale, the director now directly owns 334,646 shares in the company, valued at $14,055,132. This trade represents a 0.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Pro-Dex Price Performance

PDEX opened at $40.66 on Monday. The stock has a fifty day moving average price of $47.76 and a 200 day moving average price of $33.83. The company has a current ratio of 3.41, a quick ratio of 1.94 and a debt-to-equity ratio of 0.36. Pro-Dex, Inc. has a 1 year low of $16.18 and a 1 year high of $59.60. The stock has a market cap of $132.55 million, a price-to-earnings ratio of 26.40 and a beta of 0.56.

Institutional Investors Weigh In On Pro-Dex

Institutional investors have recently made changes to their positions in the company. FMR LLC grew its position in Pro-Dex by 34.9% in the third quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock worth $119,000 after acquiring an additional 1,028 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Pro-Dex by 7.9% in the 2nd quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier’s stock worth $240,000 after purchasing an additional 900 shares during the last quarter. Bard Associates Inc. boosted its holdings in shares of Pro-Dex by 17.6% during the 3rd quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier’s stock worth $406,000 after buying an additional 2,031 shares during the period. Ritholtz Wealth Management bought a new position in Pro-Dex in the 4th quarter worth $572,000. Finally, JPMorgan Chase & Co. lifted its position in Pro-Dex by 2.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier’s stock worth $740,000 after acquiring an additional 529 shares during the last quarter. 15.28% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

PDEX has been the topic of several recent analyst reports. StockNews.com upgraded Pro-Dex from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 14th. Ascendiant Capital Markets lifted their target price on Pro-Dex from $30.00 to $52.00 and gave the company a “buy” rating in a research note on Monday, November 11th.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.